NCT04352036

Brief Summary

Our primary objective with this cohort will be to define the different phenotypes of acute hidrosadenitis, the characterization of which is essential to define suitable therapeutic approaches. Indeed, our recent data allow us to note that there would be different phenotypes of acute hidrosadenitis and therefore different pathologies inducing different follow-ups and care.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
465

participants targeted

Target at P75+ for all trials

Timeline
46mo left

Started Jan 2022

Longer than P75 for all trials

Geographic Reach
1 country

13 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress53%
Jan 2022Feb 2030

First Submitted

Initial submission to the registry

April 10, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 17, 2020

Completed
1.7 years until next milestone

Study Start

First participant enrolled

January 4, 2022

Completed
8.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2030

Last Updated

September 5, 2025

Status Verified

August 1, 2025

Enrollment Period

8.1 years

First QC Date

April 10, 2020

Last Update Submit

August 28, 2025

Conditions

Acute Hidrosadenitis

Outcome Measures

Primary Outcomes (8)

  • Description of the natural history and identification of the different clinical forms of acute hidrosadenitis

    history of the disease, classification of Hurley, Canoui-Poitrine and van der Zee and Jemec

    through study completion, an average of 3 years

  • Prevalence of severe forms (grade II, III)

    Number of patients with severe disease (grades II and III)

    through study completion, an average of 3 years

  • Definition of different phenotypes of acute hidrosadenitis

    patient history, Canoui-Poitrine and van der Zee and Jemec classification, blood and urine tests, imaging

    through study completion, an average of 3 years

  • Identify the environmental factors associated with the chronicity of the disease

    socio-demographic data

    through study completion, an average of 3 years

  • Identify the environmental factors associated with the chronicity of the disease

    questionnaire for collecting dietary habits

    through study completion, an average of 3 years

  • Identify the environmental factors associated with the chronicity of the disease

    biological nutritional assessment research for a dysmetabolic syndrome

    through study completion, an average of 3 years

  • Identify the environmental factors associated with the chronicity of the disease

    research for a dysmetabolic syndrome

    through study completion, an average of 3 years

  • Identify the environmental factors associated with the chronicity of the disease

    lifestyle questionnaire assessing the impact on quality of life

    through study completion, an average of 3 years

Study Arms (1)

patient

Other: no interventional study

Interventions

no interventional studyOTHER

no interventional study

patient

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The population studied will relate to patients consulting or being hospitalized for Acute Hidrosadenitis, whatever its severity.

You may qualify if:

  • Patient diagnosed with acute hidrosadenitis by a dermatologist
  • Patient agreeing to be part of the study

You may not qualify if:

  • Major under guardianship
  • Protected persons

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

CHU Angers

Angers, 49933, France

RECRUITING

Chru Brest

Brest, France

RECRUITING

CHD Vendée

La Roche-sur-Yon, France

RECRUITING

CH La Rochelle

La Rochelle, France

RECRUITING

CH

Le Mans, France

RECRUITING

CH bretagne sud

Lorient, France

RECRUITING

CHU de Nantes - Dermatologie

Nantes, France

RECRUITING

Chr D'Orléans

Orléans, France

RECRUITING

CHU Milétrie

Poitiers, France

RECRUITING

Ch de Cornouaille

Quimper, France

RECRUITING

CHU Pontchaillou

Rennes, France

RECRUITING

Ch Saint-Brieuc

Saint-Brieuc, France

RECRUITING

CHRU Tours

Tours, France

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

skin biopsies and bacteriological samples

Central Study Contacts

Brigitte Dreno, PU-PH

CONTACT

0240083118brigitte.dreno@wanadoo.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 10, 2020

First Posted

April 17, 2020

Study Start

January 4, 2022

Primary Completion (Estimated)

February 20, 2030

Study Completion (Estimated)

February 20, 2030

Last Updated

September 5, 2025

Record last verified: 2025-08

Locations

FR(13)